Combination of RNase Binase and AKT1/2 Kinase Inhibitor Blocks Two Alternative Survival Pathways in Kasumi-1 Cells
Treatment of malignant neoplasms often requires the use of combinations of chemotherapeutic agents. However, in order to select combinations that are effective against specific tumor cells, it is necessary to understand the mechanisms of action of the drugs that make up the combination. Bacillus pumilus ribonuclease (binase) is considered as an adjuvant antitumor agent, and the sensitivity of malignant cells to the apoptogenic effect of binase depends on the presence of certain oncogenes. In the acute myelogenous leukemia cell line Kasumi-1, binase blocks the proliferation pathway mediated by the mutant tyrosine kinase KIT, which, as shown in our work, activates an alternative proliferation pathway through AKT kinase. In Kasumi-1 cells, binase in combination with an Akt1/2 inhibitor induces apoptosis, and their toxic effects add up: the Akt1/2 inhibitor blocks the binase-induced pathway after suppression of the KIT-dependent pathway. Thus, a combination of binase and AKT kinase inhibitors can effectively block various pathways of tumor cell proliferation and be used for their elimination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Molekuliarnaia biologiia - 56(2022), 5 vom: 01. Sept., Seite 764-773 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Mitkevich, V A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2022 Date Revised 28.09.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.31857/S002689842205010X |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346806747 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346806747 | ||
| 003 | DE-627 | ||
| 005 | 20231226032327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.31857/S002689842205010X |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346806747 | ||
| 035 | |a (NLM)36165015 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Mitkevich, V A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination of RNase Binase and AKT1/2 Kinase Inhibitor Blocks Two Alternative Survival Pathways in Kasumi-1 Cells |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2022 | ||
| 500 | |a Date Revised 28.09.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Treatment of malignant neoplasms often requires the use of combinations of chemotherapeutic agents. However, in order to select combinations that are effective against specific tumor cells, it is necessary to understand the mechanisms of action of the drugs that make up the combination. Bacillus pumilus ribonuclease (binase) is considered as an adjuvant antitumor agent, and the sensitivity of malignant cells to the apoptogenic effect of binase depends on the presence of certain oncogenes. In the acute myelogenous leukemia cell line Kasumi-1, binase blocks the proliferation pathway mediated by the mutant tyrosine kinase KIT, which, as shown in our work, activates an alternative proliferation pathway through AKT kinase. In Kasumi-1 cells, binase in combination with an Akt1/2 inhibitor induces apoptosis, and their toxic effects add up: the Akt1/2 inhibitor blocks the binase-induced pathway after suppression of the KIT-dependent pathway. Thus, a combination of binase and AKT kinase inhibitors can effectively block various pathways of tumor cell proliferation and be used for their elimination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute myelogenous leukemia | |
| 650 | 4 | |a cancer therapy | |
| 650 | 4 | |a malignant cell | |
| 650 | 4 | |a proliferation pathway | |
| 650 | 4 | |a ribonuclease | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Endoribonucleases |2 NLM | |
| 650 | 7 | |a EC 3.1.- |2 NLM | |
| 650 | 7 | |a Ribonucleases |2 NLM | |
| 650 | 7 | |a EC 3.1.- |2 NLM | |
| 650 | 7 | |a ribonuclease T(2) |2 NLM | |
| 650 | 7 | |a EC 3.1.27.1 |2 NLM | |
| 700 | 1 | |a Petrushanko, I Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Engelhardt, M G |e verfasserin |4 aut | |
| 700 | 1 | |a Kechko, O I |e verfasserin |4 aut | |
| 700 | 1 | |a Makarov, A A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molekuliarnaia biologiia |d 1975 |g 56(2022), 5 vom: 01. Sept., Seite 764-773 |w (DE-627)NLM000033979 |x 0026-8984 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2022 |g number:5 |g day:01 |g month:09 |g pages:764-773 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.31857/S002689842205010X |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2022 |e 5 |b 01 |c 09 |h 764-773 | ||